Authors' Affiliations: Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China; and Department of Molecular Carcinogenesis, the University of Texas MD Anderson Cancer Center, Science Park, Smithville, Texas
Authors' Affiliations: Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China; and Department of Molecular Carcinogenesis, the University of Texas MD Anderson Cancer Center, Science Park, Smithville, Texas.
Cancer Res. 2014 Jun 1;74(11):2922-7. doi: 10.1158/0008-5472.CAN-14-0266. Epub 2014 Apr 8.
Elucidating the origin of and dynamic interrelationship between intratumoral cell subpopulations has clear clinical significance in helping to understand the cellular basis of treatment response, therapeutic resistance, and tumor relapse. Cancer stem cells (CSC), together with clonal evolution driven by genetic alterations, generate cancer cell heterogeneity commonly observed in clinical samples. The 2013 Shanghai International Symposium on Cancer Stem Cells brought together leaders in the field to highlight the most recent progress in phenotyping, characterizing, and targeting CSCs and in elucidating the relationship between the cell-of-origin of cancer and CSCs. Discussions from the symposium emphasize the urgent need in developing novel therapeutics to target the constantly evolving CSCs.
阐明肿瘤内细胞亚群的起源和动态相互关系，对于帮助理解治疗反应、治疗耐药性和肿瘤复发的细胞基础具有明确的临床意义。癌症干细胞 (CSC) 与遗传改变驱动的克隆进化一起，产生了临床上常见的肿瘤细胞异质性。2013 年上海癌症干细胞国际研讨会汇集了该领域的领导者，重点介绍了在表型分析、特征描述和靶向 CSC 方面的最新进展，并阐明了癌症起源细胞与 CSC 之间的关系。会议讨论强调了迫切需要开发针对不断进化的 CSC 的新型治疗方法。
